Aristotle Capital Management LLC Has $661.68 Million Position in Danaher Corporation $DHR

Aristotle Capital Management LLC trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 5.8% during the first quarter, HoldingsChannel.com reports. The firm owned 3,489,816 shares of the conglomerate’s stock after selling 215,323 shares during the period. Aristotle Capital Management LLC’s holdings in Danaher were worth $661,681,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Enterprise Financial Services Corp increased its position in Danaher by 1.4% during the 4th quarter. Enterprise Financial Services Corp now owns 3,219 shares of the conglomerate’s stock valued at $737,000 after purchasing an additional 46 shares during the period. Kennebec Savings Bank lifted its stake in Danaher by 1.4% during the 4th quarter. Kennebec Savings Bank now owns 3,348 shares of the conglomerate’s stock valued at $766,000 after acquiring an additional 46 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Danaher by 2.6% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,870 shares of the conglomerate’s stock worth $428,000 after acquiring an additional 47 shares during the last quarter. High Note Wealth LLC grew its stake in shares of Danaher by 19.2% in the 4th quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock worth $67,000 after acquiring an additional 47 shares in the last quarter. Finally, First Command Advisory Services Inc. lifted its position in shares of Danaher by 4.4% during the fourth quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock valued at $253,000 after purchasing an additional 47 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. UBS Group lowered their target price on Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Citigroup started coverage on Danaher in a research report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target for the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Danaher in a report on Tuesday, April 21st. Finally, Weiss Ratings upgraded Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Danaher Trading Down 0.3%

Shares of NYSE DHR opened at $191.87 on Friday. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market cap of $134.88 billion, a P/E ratio of 34.08, a price-to-earnings-growth ratio of 2.40 and a beta of 0.79. The firm has a 50-day moving average of $185.64 and a 200 day moving average of $197.04. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.52.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.77 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a dividend of $0.40 per share. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.8%. Danaher’s dividend payout ratio is currently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.